Earnings summaries and quarterly performance for PERRIGO Co.
Executive leadership at PERRIGO Co.
Patrick Lockwood-Taylor
Detailed
President and Chief Executive Officer
CEO
Abbie Lennox
Detailed
Executive Vice President and Chief Scientific Officer
Charles Atkinson
Detailed
Executive Vice President, General Counsel and Company Secretary
David Ball
Detailed
Executive Vice President and Chief Brand and Digital Officer
Eduardo Bezerra
Detailed
Executive Vice President and Chief Financial Officer
Matt Winterman
Detailed
Executive Vice President, Product Supply, Operations Strategy & Transformation Officer
Roberto Khoury
Detailed
Executive Vice President and Chief Commercial Officer
Board of directors at PERRIGO Co.
Adriana Karaboutis
Detailed
Director
Albert Manzone
Detailed
Director
Bradley Alford
Detailed
Director
Donal O'Connor
Detailed
Director
Geoffrey Parker
Detailed
Director
Jeffrey Kindler
Detailed
Director
Jonas Samuelson
Detailed
Director
Julia Brown
Detailed
Director
Kevin Egan
Detailed
Director
Orlando Ashford
Detailed
Chairman of the Board
Research analysts who have asked questions during PERRIGO Co earnings calls.
Daniel Biolsi
Hedgeye Risk Management
3 questions for PRGO
Also covers: BRCC, STKL
Ethan Brown
JPMorgan Chase & Co.
3 questions for PRGO
Also covers: OGN
Susan Anderson
Canaccord Genuity Group
3 questions for PRGO
Also covers: BODI, CDXC, COTY +13 more
Keith Devas
Jefferies Financial Group Inc.
2 questions for PRGO
Also covers: KVUE, PBH
Korinne Wolfmeyer
Piper Sandler & Co.
2 questions for PRGO
Also covers: AIRS, BBWI, CHD +14 more
Christopher Schott
JPMorgan Chase & Co.
1 question for PRGO
Also covers: ABBV, AMGN, AMRX +15 more
Keith Davos
Jefferies
1 question for PRGO
Also covers: IDXX
Sarah Morin
Piper Sandler Companies
1 question for PRGO
Also covers: OLLI
Recent press releases and 8-K filings for PRGO.
Perrigo Faces Class Action Lawsuit Over Infant Formula Business Allegations
PRGO
Legal Proceedings
- A class action lawsuit has been filed against Perrigo Company plc, covering a Class Period from February 27, 2023, to November 4, 2025.
- The complaint alleges that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs, as well as manufacturing deficiencies.
- It is claimed that Perrigo needed to make substantial capital and operational expenditures beyond stated estimates to remediate the infant formula business, which resulted in overstated financial results, including earnings and cash flow.
- The deadline for investors to file a lead plaintiff motion in this class action is January 16, 2026.
1 day ago
Perrigo Faces Class Action Lawsuit Following Disappointing Q3 Results and Infant Formula Business Review
PRGO
Legal Proceedings
Guidance Update
Demand Weakening
- A class action lawsuit has been initiated against Perrigo Company plc, covering a class period from February 27, 2023, to November 4, 2025, with a lead plaintiff deadline of January 16, 2026.
- The complaint alleges that Perrigo failed to disclose significant underinvestment and manufacturing deficiencies in its infant formula business, requiring substantial additional capital expenditures and resulting in overstated financial results.
- On November 5, 2025, Perrigo announced disappointing financial results for the third quarter ended September 27, 2025, and slashed its fiscal year 2025 outlook due to infant formula industry dynamics.
- The company is also initiating a strategic review of its infant formula business, reassessing a previously announced $240 million investment, which caused the stock price to fall 25.2% to $15.10 per share on November 5, 2025.
4 days ago
Perrigo Company plc Faces Class Action Lawsuit Over Infant Formula Business
PRGO
Legal Proceedings
Guidance Update
Demand Weakening
- A class action lawsuit has been filed against Perrigo Company plc (PRGO) and its executives for alleged violations of the Securities Exchange Act of 1934 during the Class Period of February 27, 2023, and November 4, 2025.
- The lawsuit alleges that Perrigo made false and/or misleading statements regarding its infant formula business, acquired from Nestlé, specifically concerning underinvestment, required substantial remediation expenditures, and manufacturing deficiencies.
- The complaint highlights several disclosures, including a February 27, 2024, announcement of $35 million to $45 million in remediation costs and a 50% decline in EPS.
- On November 5, 2025, Perrigo announced a strategic review of its infant formula business, reassessing a $240 million investment, and slashed its fiscal year 2025 outlook for net sales growth and adjusted diluted earnings per share.
- Investors with substantial losses have until January 16, 2026, to seek appointment as lead plaintiff.
4 days ago
Perrigo Company plc Faces Class Action Lawsuit Over Infant Formula Business
PRGO
Legal Proceedings
Guidance Update
Profit Warning
- Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Perrigo Company plc (PRGO) and certain executives on behalf of purchasers or acquirers of PRGO securities between February 27, 2023, and November 4, 2025.
- The lawsuit alleges that Perrigo made false or misleading statements and failed to disclose significant issues with its acquired Nestlé infant formula business, including underinvestment, substantial remediation costs, and manufacturing deficiencies, which led to overstated financial results.
- The company's stock price experienced significant declines following disclosures related to the infant formula business, including a more than 15% fall on February 27, 2024, a nearly 10% fall on May 7, 2024, a more than 11% fall on August 6, 2025, and a more than 25% fall on November 5, 2025.
- On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, revising net sales growth guidance to -2.5% to -3% (from 0% to 3%) and adjusted diluted earnings per share to $2.70 to $2.80 (from $2.90 to $3.10).
- Investors who suffered substantial losses have until January 16, 2026, to seek appointment as lead plaintiff in the lawsuit.
Dec 6, 2025, 2:50 PM
Perrigo Faces Class Action Lawsuit Over Securities Fraud Allegations
PRGO
Legal Proceedings
Profit Warning
New Projects/Investments
- A class action lawsuit has been filed against Perrigo Company plc (PRGO), alleging securities fraud or other unlawful business practices.
- Investors who acquired Perrigo securities during the Class Period have until January 16, 2026, to apply to the Court to be appointed as Lead Plaintiff.
- The lawsuit stems from several events, including a 50% decline in fiscal year 2023 earnings per share due to infant formula remediation actions, and a $30 million (6.9%) decrease in adjusted gross profit in the second quarter of 2025 due to production variability in infant formula.
- Most recently, on November 5, 2025, Perrigo's stock price fell $5.09 per share, or 25.2%, after the company announced a strategic review of its infant formula business and a reassessment of a previously announced $240 million investment in this business.
Nov 18, 2025, 9:43 PM
Perrigo Company plc Faces Class Action Lawsuit Over Infant Formula Business
PRGO
Legal Proceedings
Profit Warning
Demand Weakening
- Robbins LLP has filed a class action lawsuit against Perrigo Company plc (NYSE: PRGO) on behalf of investors who purchased securities between February 27, 2024, and November 4, 2025.
- The lawsuit alleges Perrigo misled investors by failing to disclose significant underinvestment and manufacturing deficiencies in its infant formula business, leading to overstated financial results.
- On November 5, 2025, Perrigo announced disappointing Q3 2025 financial results, slashed its fiscal year 2025 outlook, and initiated a strategic review of its infant formula business, reassessing a $240 million investment.
- Following these announcements, Perrigo's stock price fell $5.09, or 25.2%, to close at $15.10 per share on November 5, 2025.
Nov 18, 2025, 11:45 AM
Perrigo Reports Q3 2025 Results, Revises Full-Year Outlook, and Initiates Strategic Review of Infant Formula Business
PRGO
Earnings
Guidance Update
Demand Weakening
- Perrigo reported Q3 2025 EPS of $0.80, a slight decrease from the prior year, while year-to-date EPS grew 21% (or 27% organically) to $1.97.
- Organic net sales for Q3 2025 declined 4.4%, primarily due to soft OTC category consumption and impacts from businesses under strategic review.
- The company revised its 2025 outlook, expecting organic net sales growth of -2.5% and a full-year EPS range of $2.70-$2.80, citing softer OTC consumption and slower Infant Formula share recovery.
- Perrigo is actively reviewing its Infant Formula business, pausing a previously announced $240 million investment, and expects the sale of its dermocosmetics business to close in Q1 2026, with net proceeds allocated to debt reduction.
- Despite challenging market conditions, Perrigo's U.S. OTC store brand achieved six consecutive months of share gains, and its key European brands gained dollar share for five consecutive months.
Nov 5, 2025, 1:30 PM
Perrigo Reports Q3 2025 Results, Revises Full-Year Outlook, and Initiates Infant Formula Strategic Review
PRGO
Guidance Update
Demand Weakening
M&A
- Perrigo reported Q3 2025 EPS of $0.80, off one penny versus the prior year, and year-to-date EPS of $1.97, representing 21% growth (or 27% organically).
- Organic net sales declined 4.4% in Q3 2025, primarily impacted by soft OTC category consumption and businesses under review.
- The company revised its 2025 outlook, now expecting organic net sales growth of -2.5%, a gross margin of approximately 39%, and an EPS range of $2.70-$2.80. This revision is attributed to softer than anticipated OTC consumption and slower infant formula share growth.
- Perrigo announced an active strategic review of its infant formula business, pausing a $240 million investment, while the sale of its dermocosmetics business remains on track to close in Q1 2026.
- Despite challenging market conditions, Perrigo achieved sustained share gains in US OTC, gaining 90 basis points of volume share over the last 13 weeks, and its key European brands gained dollar share for five consecutive months.
Nov 5, 2025, 1:30 PM
Perrigo Reports Q3 2025 Results, Revises Full-Year Outlook, and Initiates Infant Formula Strategic Review
PRGO
Earnings
Guidance Update
M&A
- Perrigo reported Q3 2025 adjusted EPS of $0.80 and year-to-date adjusted EPS of $1.97, marking 21% growth year-over-year.
- The company revised its 2025 outlook, now projecting organic net sales growth of -2.5% and an adjusted EPS range of $2.70-$2.80, primarily due to softer-than-expected OTC category consumption and slower infant formula share recovery.
- Perrigo announced a strategic review of its infant formula business, pausing a $240 million investment, and confirmed the dermocosmetics divestiture is on track to close in Q1 2026.
- Despite a challenging market with soft OTC consumption, Perrigo achieved share gains in its US OTC store brand business and key European brands.
Nov 5, 2025, 1:30 PM
Perrigo Reports Q3 2025 Results and Updates Full-Year Outlook Amid Strategic Reviews
PRGO
Earnings
Guidance Update
M&A
- Perrigo reported Q3 2025 net sales of $1.04 billion, a 4.1% decrease year-over-year, with organic net sales down 4.4%.
- For Q3 2025, reported diluted EPS was $0.09 (improved from $(0.13) in the prior year), and adjusted diluted EPS was $0.80 (down from $0.81).
- The company updated its full-year 2025 outlook, projecting net sales growth of -2.5% to -3.0% and adjusted EPS of $2.70 to $2.80, primarily due to infant formula industry dynamics and soft Over-The-Counter (OTC) market consumption trends.
- Perrigo initiated a strategic review of its Infant Formula Business and continues the strategic review of its Oral Care Business, while remaining on track to close the previously announced sale of its Dermacosmetics Business in Q1'26.
Nov 5, 2025, 11:44 AM
Quarterly earnings call transcripts for PERRIGO Co.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more